Randomized Trialhigh evidence
Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
Lancet (London, England)·October 17, 2026·PMID 42815506
Why it mattersCardiovascular safety is a critical requirement for new glucose-lowering agents, especially in patients with established cardiovascular or chronic kidney disease. This trial provides the first cardiovascular outcomes data for a non-peptide oral GLP-1 receptor agonist, confirming non-inferiority to insulin glargine and supporting orforglipron as an oral option with a favorable hypoglycemia profile.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled